Publication:
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

dc.contributor.authorMohty, Mohamad
dc.contributor.authorTerpos, Evangelos
dc.contributor.authorMateos, Maria-Victoria
dc.contributor.authorCavo, Michele
dc.contributor.authorLejniece, Sandra
dc.contributor.authorBeksac, Meral
dc.contributor.authorBekadja, Mohamed Amine
dc.contributor.authorLegiec, Wojciech
dc.contributor.authorDimopoulos, Meletios
dc.contributor.authorStankovic, Svetlana
dc.contributor.authorDurán, Maria Soledad
dc.contributor.authorDe Stefano, Valerio
dc.contributor.authorCorso, Alessandro
dc.contributor.authorKochkareva, Yulia
dc.contributor.authorLaane, Edward
dc.contributor.authorBerthou, Christian
dc.contributor.authorSalwender, Hans
dc.contributor.authorMasliak, Zvenyslava
dc.contributor.authorPečeliūnas, Valdas
dc.contributor.authorWillenbacher, Wolfgang
dc.contributor.authorSilva, João
dc.contributor.authorLouw, Vernon
dc.contributor.authorNemet, Damir
dc.contributor.authorBorbényi, Zita
dc.contributor.authorAbadi, Uri
dc.contributor.authorPedersen, Robert Schou
dc.contributor.authorČernelč, Peter
dc.contributor.authorPotamianou, Anna
dc.contributor.authorCouturier, Catherine
dc.contributor.authorFeys, Caroline
dc.contributor.authorThoret-Bauchet, Florence
dc.contributor.authorBoccadoro, Mario
dc.contributor.authorEMMOS Investigators
dc.date.accessioned2023-01-25T10:21:00Z
dc.date.available2023-01-25T10:21:00Z
dc.date.issued2018-06-25
dc.description.abstractThe present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.
dc.identifier.doi10.1016/j.clml.2018.06.018
dc.identifier.essn2152-2669
dc.identifier.pmid30030033
dc.identifier.unpaywallURLhttp://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152265018302301/pdf
dc.identifier.urihttp://hdl.handle.net/10668/12733
dc.issue.number10
dc.journal.titleClinical lymphoma, myeloma & leukemia
dc.journal.titleabbreviationClin Lymphoma Myeloma Leuk
dc.language.isoen
dc.organizationHospital Universitario de Jaén
dc.page.numbere401-e419
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeObservational Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectBortezomib
dc.subjectGlobal
dc.subjectObservational study
dc.subjectRoutine practice
dc.subjectStem cell transplantation
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBoronic Acids
dc.subject.meshBortezomib
dc.subject.meshDexamethasone
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshLenalidomide
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMultiple Myeloma
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshPractice Patterns, Physicians'
dc.subject.meshProspective Studies
dc.subject.meshSalvage Therapy
dc.subject.meshSurvival Rate
dc.subject.meshThalidomide
dc.subject.meshTreatment Outcome
dc.titleMultiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number18
dspace.entity.typePublication

Files